Cesium carbonate → 1-[2-(4-Methoxyphenyl)ethyl]-2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
반응식
[CH3:1][C:2]1([CH3:18])[CH2:17][N:5]2[C:6](=[O:16])[CH:7]=[C:8]([N:10]3[CH2:15][CH2:14][O:13][CH2:12][CH2:11]3)[N:9]=[C:4]2[NH:3]1.[CH3:19][O:20][C:21]1[CH:29]=[CH:28][C:24]([CH2:25][CH2:26]Br)=[CH:23][CH:22]=1.C(=O)([O-])[O-].[Cs+].[Cs+]>>[CH3:19][O:20][C:21]1[CH:29]=[CH:28][C:24]([CH2:25][CH2:26][N:3]2[C:4]3=[N:9][C:8]([N:10]4[CH2:15][CH2:14][O:13][CH2:12][CH2:11]4)=[CH:7][C:6](=[O:16])[N:5]3[CH2:17][C:2]2([CH3:18])[CH3:1])=[CH:23][CH:22]=1참가 물질
4
실험 절차
The product is prepared according to the procedure described in Example 1, using 100 mg of 2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one and 0.94 ml of 4-methoxyphenethyl bromide, replacing the sodium hydride with caesium carbonate. After purification by silica column chromatography (eluent: dichloromethane/methanol: 98/02), 39 mg of 1-[2-(4-methoxyphenyl)ethyl]-2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one are obtained, the characteristics of which are the following: